医学
肉芽肿伴多发性血管炎
美罗华
嗜酸性
梅德林
科克伦图书馆
内科学
潘卡
队列
回顾性队列研究
血管炎
系统回顾
队列研究
批判性评价
皮肤病科
显微镜下多血管炎
抗中性粒细胞胞浆抗体
胃肠病学
重症监护医学
作者
Vincenzo G Menditto,Giulia Rossetti,Diletta Olivari,Alessia Angeletti,Marco B. L. Rocchi,Armando Gabrielli,Giovanni Pomponio
出处
期刊:Rheumatology
[Oxford University Press]
日期:2021-04-06
卷期号:60 (4): 1640-1650
被引量:11
标识
DOI:10.1093/rheumatology/keab046
摘要
Abstract Objective To analyse the available evidence about the use of rituximab (RTX) and other biologic agents in eosinophilic granulomatosis with polyangiitis (EGPA) patients and to provide useful findings to inform the design of future, reliable clinical trials. Methods A systematic review was performed. A systematic search was conducted in PubMed/MEDLINE, Scopus, Web of Science and the Cochrane library databases on RTX, and an extensive literature search was conducted on other biologic agents. Results Forty-five papers pertinent to our questions were found: 16 retrospective cohort studies, 8 case series, 3 prospective cohort studies and 18 single case reports, for a total of 368 EGPA patients. More than 80% of evaluable patients achieved complete or partial remission with a tendency towards a higher rate of complete response in the pANCA-positive subgroup. Conclusion Although the majority of the evaluable EGPA patients treated with RTX appears to achieve complete remission, we strongly believe that a number of sources of heterogeneity impair a clear interpretation of results and limit their transferability in clinical practice. Differences in design, enrolment criteria, outcome definition and measurement make a comparison among data obtained from studies on RTX and other biologic agents unreliable.
科研通智能强力驱动
Strongly Powered by AbleSci AI